Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Given the sema-bima results, Lilly will be competitive here
Even if GLP-1s reduce downstream costs by preventing dialysis, cardiovascular events, or hospitalisations, insurers may still apply stage-based restrictions, mandate prior use of increasingly generic SGLT2i use, or limit treatment duration
When a branded medication like Zepbound or Mounjaro is on the official shortage list, it changes the landscape for how patients can access treatment
People are suing Novo Nordisk and Eli Lilly and Company due to legal issues surrounding their GLP-1 receptor agonist drugs, with plaintiffs bringing forth substantially similar allegations against both drug manufacturers
US$ 21.72
US$ 25.51
US$ 20.75
US$ 27.45
